Clinical and laboratory observations following oral or intramuscular administration of a live attenuated hepatitis A vaccine candidate

Maria H. Sjogren, Robert H. Purcell, Kelly McKee, Leonard Binn, Philip Macarthy, John Ticehurst, Steven Feinstone, Jeffrey Caudill, Anthony See, Charles Hoke, William Bancroft, Erik D'Hondt

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Clinical observations made after immunising volunteers with a live attenuated hepatitis A vaccine are described. The candidate vaccine was prepared with the HM175 strain of hepatitis A virus and shown to be safe, immunogenic and efficacious in experimental animals. When the candidate vaccine was tested by oral administration in humans at increasing doses-104, 105, 106 and 107 median tissue culture infective doses (TCID50)-an antibody response was not observed at any dose. Volunteers who received similar doses by the intramuscular route developed antibody to hepatitis A three weeks after immunization with 106 or 107 TCID50. The antibody response was sustained for the 12 weeks of the observation period. All volunteers remained healthy with normal results from liver tests throughout the monitoring period. Further clinical observations of this product are in progress.

Original languageEnglish (US)
Pages (from-to)S135-S137
JournalVaccine
Volume10
Issue numberSUPPL. 1
DOIs
StatePublished - 1992
Externally publishedYes

Keywords

  • Hepatitis A
  • liver
  • viral hepatitis

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Clinical and laboratory observations following oral or intramuscular administration of a live attenuated hepatitis A vaccine candidate'. Together they form a unique fingerprint.

Cite this